	US 12,222,355 B2
	Therapeutic antibodies against ROR-1 protein and methods for use of same
Thomas J. Kipps, San Diego, CA (US); George F. Widhopf, II, San Diego, CA (US); and Bing Cui, San Diego, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Nov. 22, 2022, as Appl. No. 18/058,239.
Application 18/058,239 is a continuation of application No. 17/130,928, filed on Dec. 22, 2020, granted, now 11,536,727.
Application 17/130,928 is a continuation of application No. 16/777,738, filed on Jan. 30, 2020, granted, now 10,900,973, issued on Jan. 26, 2021.
Application 16/777,738 is a continuation of application No. 15/894,741, filed on Feb. 12, 2018, granted, now 10,627,409, issued on Apr. 21, 2020.
Application 15/894,741 is a continuation of application No. 15/346,967, filed on Nov. 9, 2016, granted, now 9,933,434, issued on Apr. 3, 2018.
Application 15/346,967 is a continuation of application No. 14/846,400, filed on Sep. 4, 2015, granted, now 9,523,695, issued on Dec. 20, 2016.
Application 14/846,400 is a continuation of application No. 13/997,934, granted, now 9,217,040, issued on Dec. 22, 2015, previously published as PCT/US2012/021339, filed on Jan. 13, 2012.
Claims priority of provisional application 61/433,043, filed on Jan. 14, 2011.
Prior Publication US 2023/0341412 A1, Oct. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61K 39/00 (2006.01); C07K 16/40 (2006.01); G01N 33/68 (2006.01)

CPC G01N 33/6854 (2013.01) [C07K 16/2803 (2013.01); C07K 16/40 (2013.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)]

9 Claims

1. An isolated anti-ROR1 antibody comprising a humanized heavy chain variable region and a humanized light chain variable region, wherein:

a) said heavy chain variable region comprises complementarity determining regions corresponding to amino acids 26 to 33, 51 to 57, and 96 to 106 of SEQ ID NO: 14, and said light chain variable region comprises complementarity determining regions corresponding to amino acids 26 to 31, 49 to 51, and 88 to 96 of SEQ ID NO: 16;

b) said heavy chain variable region comprises complementarity determining regions corresponding to amino acids 26 to 33, 51 to 58, and 97 to 108 of SEQ ID NO: 6, and said light chain variable region comprises complementarity determining regions corresponding to amino acids 27 to 32, 50 to 52, and 89 to 97 of SEQ ID NO: 8; or

c) said heavy chain variable region comprises complementarity determining regions corresponding to amino acids 26 to 33, 51 to 57, and 96 to 107 of SEQ ID NO: 18, and said light chain variable region comprises complementarity determining regions corresponding to amino acids 27 to 32, 50 to 52, and 89 to 97 of SEQ ID NO: 20.